VEGF-C delivery by several methodologies, including recombinant protein, viral vector, naked plasmid, or topical therapy transiently improved surgically induced lymphoedema in several animal species, using various lymphoedema models (Stacker et al., 2014; Brown et al., 2022). The gene discussed is VEGFC; the disease is lymphedema.